The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF Multi-stakeholder Workshop

Clinical Research in Central and Eastern Europe
New Approaches for the Next Level of Development

15-16 April 2024, Hybrid Conference

Recordings

SESSION 1: CURRENT STATUS OF CLINICAL TRIALS IN CEE

Session 1 – Welcome & Introduction

Conversation on Cancer: Accelerating Oncology Drug Development through Innovation with Dr Richard Pazdur (FDA, US) & Prof. Grzegorz S. Nowakowski (Mayo Clinic, US)

Patients in Poland – building the bridge between old and new – Joanna Frątczak-Kazana (Alivia, PL)

Impact of Ukraine conflict on clinical trials in CEE – Prof. Mark Lawler (CDDF, UK)

Session 1 – Panel discussion

Session 1 – Complete

SESSION 2: IMPROVING CLINICAL TRIALS IN CEE

Session 2 – Introduction

Ongoing challenges from the site’s perspective – Prof. Ewa Kalinka (Institute of Polish Mother’s Health Center, PL)

Initiatives to improve clinical trials in Poland – Dr Karolina Nowak (Medical Research Agency, PL)

Regulatory Initiatives – National and European Aspects – Dr Keiu Heinla (Estonian State Agency of Medicines, EE)

Session 2 – Panel discussion

Session 2 – Complete

SESSION 3: CLINICAL TRIALS IN CEE - INDUSTRY PERSPECTIVE

Global industry perspective – Wiktor Janicki (AZ, PL)

Pharmaceutical innovation in CEE with the focus on clinical trials – Dr Radek Špíšek (SOTIO, CZ)

How to build a sustainable biotech hub in an emerging economy – Poland as the new source of biomedical innovation – Pawel Przewięźlikowski (Ryvu, PL)

Session 3 – Complete

SESSION 4: INNOVATIVE CONCEPTS IN CEE

Clinical trials in CEE – opportunities and challenges – Poland as example – Dr Piotr Rutkowski (President of the Polish Society of Oncology, PL)

Accelerating global clinical trials conduct: access, decentralization and technology – Dr Grzegorz S. Nowakowski (Mayo Clinic, US)

Facilitating innovation in clinical trials – Olga Kholmanskikh (FAMHP, BE)

Patient access to innovative drugs in oncology – Bulgarian Perspective – Teodora Kolarova (International Neuroendocrine Cancer Alliance (INCA, BG)

Cross-border access to clinical trial – Dr Susan Bhatti (Merck Healthcare, NL)

Session 4 – Panel discussion

Session 4 – Complete

SESSION 5: CLINICAL TRIALS IN EUROPE - REGULATORY PERSPECTIVE

Session 5 – Complete recording

SESSION 6: ROUNDTABLE TO FORMULATE CONSENSUS FOR NEXT STEPS

Session 6 – Complete recording